← Human Trials & Peer-Reviewed Studies
Liver function, in-hospital, and post-discharge clinical outcome in patients with acute heart failure-results from the relaxin for the treatment of patients with acute heart failure study
Plain-language guide to PMID 24642379 (2014): randomized controlled trial study of Relaxin (Serelaxin) in 234 patients.
Key Facts
- PMID
- 24642379
- Journal
- Journal of cardiac failure
- Year
- 2014
- Study type
- Randomized Controlled Trial
- Authors
- van Deursen VM et al. (12 authors)
- DOI
- 10.1016/j.cardfail.2014.03.003
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at Relaxin (Serelaxin).
The researchers aimed to assess the prevalence and prognostic value of serial measurements of liver function tests in patients admitted with acute decompensated HF.
Why It Was Studied
Elevated plasma concentrations of liver function tests are prevalent in patients with chronic heart failure (HF).
Little is known about liver function in patients with acute HF.
Who Took Part
According to the abstract, 234 patients were involved.
The age groups tagged for this paper are middle-aged adults, older adults and people over 80, both men and women.
The researchers investigated liver function tests from all 234 patients from the Relaxin for the Treatment of Patients With Acute Heart Failure study at baseline and during hospitalization.
How the Study Was Run
In design terms this was a randomized study.
Random assignment meant chance, not the researchers, decided who got Relaxin (Serelaxin) and who got the comparison, which limits bias.
The end points were worsening HF through day 5, 60-day mortality or rehospitalization, and 180-day mortality.
What Was Measured
Elevated plasma concentrations of liver function tests are prevalent in patients with chronic heart failure (HF).
The subject headings attached to it are Acute Disease, Heart Failure, Hospitalization, Liver, Liver Function Tests, Patient Discharge and Relaxin.
Author keywords: acute decompensated heart failure and prognosis.
What This Means in Plain Language
The paper is a randomized study of Relaxin (Serelaxin) in 234 patients.
The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2014 (Journal of cardiac failure), a journal based in United States.
More context: the Relaxin (Serelaxin) compound page, all human trials.
Our Notes on the Compound
Relaxin (Serelaxin): A pregnancy hormone that relaxes blood vessels; serelaxin is a recombinant form studied in acute heart failure.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.